ArticleCureus2025
Primary Vaginal Melanoma or Clear Cell Sarcoma: A Difficult Differential Diagnosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower genital tract lesions are a frequent reason for gynecological consultation, and primary vaginal melanoma is an uncommon but aggressive form of malignancy. It primarily strikes in postmenopausal women and is often detected at an advanced stage, accounting for its poor prognosis. A 47-year-old Caucasian female patient was referred to our institution due to abnormal vaginal bleeding and a palpable lesion near the urethra, and subsequently, we present a case of primary vaginal melanoma. Histopathological and immunohistochemical studies confirmed the diagnosis of melanoma and differentiated it from clear cell sarcoma. Imaging showed multiple lung metastases, and the patient was restaged as stage IV vaginal melanoma. The patient was treated with anti-PD-1 agent nivolumab and anti-CTLA-4 agent ipilimumab, and after that, she showed a good clinical response. This case illustrates some of the difficulties in wade through the diagnosis and treatment of vaginal melanoma, as well as a powerful argument for obtaining early definitive biopsy and diagnosis. We discuss the treatment options, including surgical excision, radiation therapy, and immunotherapy, emphasizing the poor prognosis and low survival rates among patients diagnosed with an advanced stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.